论文部分内容阅读
５２例冠心病血瘀证患者随机分为两组，一组服纯中药制剂抗凝调脂口服液，另一组服西药力抗栓片作为对照组，治疗一个月。结果表明抗凝调脂口服液有明显抗血小板聚集作用，使血小板聚集率下降（Ｐ＜０．００１），有抗凝血及提高纤溶激活能力，使ＶＷＦ（％）由１３６．２±３１．２降低到１０５．７±２８．２，使ＡＴ—Ⅲ（ｍｇ／Ｌ）由２９３．７±８６．２升至３４２．４±６７．７，使ｔＰＡ（ｎｇ／Ｌ）由１５．１±４．９升至２１．１±３．７，使ＰＡＩ（ｕ／Ｌ）由１１．１±１．８降至８．９±２．０。本文并进一步讨论了抗凝调脂口服液的作用机理
Fifty-two patients with coronary heart disease with blood stasis syndrome were randomly divided into two groups. One group took pure Chinese medicine preparation anticoagulant lipid regulating oral liquid and the other group took Xi Yao Li antithrombotic tablet as a control group and treated for one month. The results showed that anticoagulation and lipid-adjusting oral liquid had obvious anti-platelet aggregation, decreased platelet aggregation rate (P<0.001), had anticoagulation and increased fibrinolytic activation capacity, making VWF (%) from 136.2±31 .2 Decrease to 105.7±28.2, increase AT-III (mg/L) from 293.7±86.2 to 342.4±67.7, and make tPA(ng/L) 15.1. ±4.9 rises to 21.1±3.7, reducing the PAI(u/L) from 11.1±1.8 to 8.9±2.0. This article further discussed the mechanism of action of anticoagulant lipid oral solution